Valneva SE — FY2021 Form 20-F Summary
Reporting period: Fiscal year ended December 31, 2021. This is an annual report, not a standalone fourth-quarter filing; the figures below are full-year amounts. Financial statements are audited and prepared under IFRS as issued by the IASB, in euros.
Business and financial performance
Valneva is a vaccine company that develops and commercializes prophylactic vaccines. Its marketed products are IXIARO for Japanese encephalitis and DUKORAL for cholera and, in certain markets, ETEC-related diarrhea. Its principal clinical programs are VLA15 (Lyme disease, partnered with Pfizer), VLA1553 (chikungunya) and VLA2001 (COVID-19).
| Metric | FY2021 | FY2020 |
|---|---|---|
| Total revenue | €348.1 million | €110.3 million |
| Product sales | €63.0 million | €65.9 million |
| Operating loss | €61.4 million | €55.1 million |
| Net loss | €73.4 million | €64.4 million |
| R&D expense | €173.3 million | €84.5 million |
| Cash and cash equivalents at year-end | €346.7 million | €204.4 million |
| Net cash from operating activities | €76.9 million | €137.7 million |
| Net cash used in investing activities | €93.1 million | €19.3 million |
| Net cash from financing activities | €154.5 million | €21.7 million |
Revenue rose 215.5%, principally because €253.3 million of UK Government advance payments was recognized as revenue following termination of the UK Supply Agreement. Product sales fell 4.5%. IXIARO sales declined 6.9% to €45.1 million, while DUKORAL fell 81.7% to €2.4 million; reduced travel demand was the main factor. Third-party product sales rose to €15.4 million, including €8.2 million from Bavarian Nordic products.
Reported product gross margin was 36.5%, approximately unchanged from 36.6% in 2020. By product, IXIARO gross margin was 50.0%, DUKORAL gross margin was negative 209.8%, and third-party product gross margin was 36.1%. DUKORAL’s result reflected low volumes, idle capacity and inventory impairment. The filing does not present a comparable consolidated gross margin that isolates the effects of the unusual COVID-segment revenue.
R&D expense more than doubled, led by VLA2001 (€113.9 million) and VLA1553 (€44.0 million). Capital expenditure was €92.3 million, mainly for manufacturing capacity in Scotland and Sweden. Cash from operations included UK payments and €100.8 million of European Commission member-state advance payments; it should not be viewed as recurring operating cash generation.
Liquidity, debt and capital
Year-end total assets were €817.4 million, equity €170.6 million and total liabilities €646.8 million. Borrowings were €57.8 million and lease liabilities €56.8 million. The Deerfield/OrbiMed loan carried a 9.95% stated rate (10.09% annualized under its quarterly calculation), with principal amortization beginning in 2023 and maturity in 2026. It is secured by substantially all assets, including intellectual property. Covenants include minimum liquidity of €50 million for 2021–2022 and minimum annual consolidated net revenue, excluding grants, of €64 million for 2021 and €103.75 million for 2022.
Refund liabilities were €254.6 million on the balance sheet, including €166.9 million related to uncertain obligations following UK contract termination and €79.6 million related to the Pfizer collaboration. The contractual-obligations table reports €301.1 million of undiscounted refund-liability cash flows. Management stated that year-end cash was expected to fund current plans through at least September 2023; the financial-statement liquidity assessment separately says at least 12 months from authorization for issuance.
Two 2021 equity offerings generated €166.6 million of net cash proceeds from share issuance, according to the cash-flow statement. Ordinary shares outstanding at year-end were 105,190,223. No dividend was paid or anticipated for the foreseeable future.
Material changes, outlook and risks
- UK Supply Agreement: Termination became effective October 10, 2021. Valneva recognized €253.3 million as revenue based on management’s judgment that repayment was remote, while recording €166.9 million of refund liabilities for uncertain surviving obligations, including royalties and other restrictions. Valneva disputes the UK Authority’s alleged anticipatory-breach basis; the company reported no specific damages claim as of the filing. A low-single-digit royalty on certain non-UK sales survives, capped at €100 million.
- VLA2001: The Phase 3 trial met its co-primary immunogenicity endpoints versus AstraZeneca’s vaccine: neutralizing-antibody GMT ratio 1.39 (p<0.0001), with seroconversion above 95% in both groups. The filing reported a statistically better tolerability profile. Bahrain granted emergency authorization in February 2022; EMA and MHRA reviews were ongoing, with conditional EMA authorization expected in April 2022. The European Commission agreement covers approximately 24.3 million doses for 2022 and an option for 35.7 million in 2023, subject to authorization, delivery and other terms. Supply deadlines, manufacturing execution and possible refunds or damages are material risks.
- VLA1553: Valneva reported positive Phase 3 results, including 98.9% seroprotection at Day 29 and 96.3% at six months. The company intended to seek FDA approval using an accelerated-approval pathway and expected a U.S. filing later in 2022. Approval, confirmatory-trial requirements and a potential Priority Review Voucher remained uncertain.
- VLA15: Developed with Pfizer, which leads late-stage development and controls commercialization. Valneva funds 30% of development costs. The company expected Phase 3 to begin in the third quarter of 2022; positive results and future milestone and royalty revenues are not assured.
- Continued losses and funding: Valneva reported accumulated net losses of €307.0 million and expects significant operating losses for several years. Travel recovery, vaccine approvals and sales, clinical outcomes, manufacturing capacity, supply-chain dependencies and access to additional capital could materially affect results. DUKORAL and IXIARO sales remained vulnerable to travel restrictions and competition.
- Controls and litigation: Disclosure controls were assessed as ineffective at year-end because of material weaknesses. One of three previously identified internal-control weaknesses was remediated; weaknesses involving formal processes and manual journal-entry segregation remained. The filing also describes merger-related shareholder litigation and a separate Humalys acquisition claim; outcomes are uncertain.
Investor verification priorities
- Reconcile the €253.3 million UK termination revenue recognition with the €166.9 million refund liability, the remaining contractual obligations and any subsequent settlement or legal developments.
- Check actual VLA2001 regulatory decisions, deliveries, cancellations, refunds and manufacturing performance against the European Commission agreement’s deadlines and conditions.
- Assess underlying revenue and cash generation excluding UK termination accounting, government advance payments, equity proceeds and other non-recurring items.
- Monitor travel-vaccine demand, especially DUKORAL’s severe sales decline and gross-margin impact, alongside the pace of recovery in international travel.
- Track R&D spending, cash burn, covenant compliance, debt service and the timing and cost of manufacturing investment against the stated cash runway.
- Verify progress in remediating the remaining internal-control weaknesses and follow the merger-related and Humalys legal proceedings.